CDNA · CareDx, Inc. · Stock research

Current Thesis

CareDx is the donor-derived cell-free DNA (dd-cfDNA) transplant-surveillance leader (AlloSure Kidney/Heart/Lung, AlloMap Heart). Its entire multiple has been hostage since 2023 to one question: will Medicare reimburse frequent surveillance testing, or only for-cause? On 2026-07-16 the MolDX Local Coverage Determination was finalized (effective 2026-08-30) affirming surveillance coverage across kidney, heart and lung the single overhang that collapsed the stock from ~$70 (2023) to a $10.96 low is now lifted. Shares re-rated roughly +28% in one session to $39.73 (2026-07-17), pinned to the 52-week high of $40.47. The re-rating is structurally real, but the catalyst has already printed: this is now a post-event tape sitting at the highs, above the entire analyst stack bar one, into a binary 2026-08-05 Q2 report. Strength here is a chase, not a front-run.

Bullish and bearish views on CareDx, Inc.

The model's bull view on CareDx, Inc. (CDNA), in brief: The overhang is gone. Finalized MolDX LCD published 2026-07-16, effective 2026-08-30, affirms surveillance dd-cfDNA coverage for kidney/heart/lung recipients removing the reimbursement uncertainty that has capped the multiple for three years. This is a genuine structural… The bear view: The catalyst already fired. Spot $39.73 (2026-07-17) is glued to the 52-week high ($40.47) after a single-bar +28% gap. Buying here is paying for the re-rate after it happened, the opposite of this book's 3-6-weeks-early edge. Price is ahead of the sell-side, not behind it.… Both cases follow in full.

Bull Case

• The overhang is gone. Finalized MolDX LCD published 2026-07-16, effective 2026-08-30, affirms surveillance dd-cfDNA coverage for kidney/heart/lung recipients removing the reimbursement uncertainty that has capped the multiple for three years. This is a genuine structural re-rate, not a headline pop.
• Guidance already moving up. FY2026 revenue guide raised to $447–465M (from $420–444M) with adj. EBITDA $43–57M; management flags the LCD as only a ~$7.5M six-month partial 2026 impact the full-year 2027 volume/reimbursement tailwind is materially larger.
• Cleaner franchise. Lab Products operations sold to Eurobio Scientific for $171.2M, closed 2026-06-30 cash in, and the story narrows to the higher-margin testing business ahead of the 2026-08-05 pro-forma disclosure.
• Sell-side lags the re-rate. BTIG lifted its target $28 → $45 on 2026-07-16; consensus 12-month PT still sits at ~$29.60, so the upward-revision stream (the "analysts catch up" leg) has barely started.
• Volume base. Revenue TTM $412.8M on a testing franchise where reimbursement certainty directly supports higher surveillance frequency per patient a volume compounding tailwind into 2027.

Bear Case

• The catalyst already fired. Spot $39.73 (2026-07-17) is glued to the 52-week high ($40.47) after a single-bar +28% gap. Buying here is paying for the re-rate after it happened, the opposite of this book's 3-6-weeks-early edge.
• Price is ahead of the sell-side, not behind it. Consensus PT $29.60 sits ~25% below spot; only the freshest BTIG note ($45) is above. When price leads every target but one, mean-reversion risk is elevated.
• Binary print 18 days out. Q2 reports 2026-08-05. The LCD's H2 partial ($7.5M) barely touches Q2 actuals the print turns on volume and margin execution, and a soft FY tone unwinds the euphoria fast.
• Not yet profitable. Net income -$8.19M TTM, EPS -$0.16 — this is a re-rating on reimbursement certainty, not demonstrated earnings power.
• Reimbursement euphoria has round-tripped here before. The 2023 LCD cut erased ~85% of the market cap; CMS/MolDX policy giveth and taketh, and any contractor clarification narrowing surveillance coverage reverses the whole thesis.

Setup & Price Structure

• Spot ~$39.73 (2026-07-17), pinned to the 52-week high $40.47; 52-week low $10.96 a near-4x off the lows over the trailing twelve months.
• The 2026-07-16 session gapped from a ~$29.56 intraday low to a $39.87 close on the LCD news, leaving an unfilled gap roughly between $30 and $37.
• Vertically extended above all moving averages after a one-bar move; no base has formed above $37, and momentum is overbought by any read.
• The prior consolidation shelf sits ~$28–30 (BTIG's old $28 target anchored here) that zone is the line that defines whether the re-rate holds or fills.
• Market cap ~$2.05B on 51.66M shares outstanding.

Catalyst Calendar (next 30 days)

• 2026-08-05 Q2 2026 earnings (binary). Pro-forma detail on the Lab Products divestiture expected on the call. ~18 days out; the dominant near-term event.
• 2026-08-30 MolDX LCD effective date; surveillance coverage formally begins.
• Rolling sell-side target revisions post-LCD; laggards clustered near the ~$29.60 average likely revise up toward the fresh BTIG $45.

What Would Change Our Mind

• A weekly close back below $30 fills the 2026-07-16 LCD gap and negates the coverage re-rating.
• A Q2 miss or soft FY guide on 2026-08-05 showing surveillance-volume deceleration despite the coverage win.
• Any CMS/MolDX walk-back or contractor clarification narrowing the surveillance-testing coverage grant.
• The diagnostics-reimbursement narrative going fully mainstream/saturated with no fresh volume data to support the multiple.

Correlation Notes

• Idiosyncratic regulatory catalyst low correlation to broad medtech or XBI biotech beta; the driver is CMS/MolDX policy, not rates or risk appetite.
• Direct peer read: Natera (NTRA) via its Prospera transplant dd-cfDNA test a favorable surveillance LCD is a rising-tide signal for transplant dd-cfDNA broadly, though CareDx is the volume leader. Loosely tracks reimbursement-sensitive molecular-diagnostics names Veracyte (VCYT) and Guardant (GH).
• This is a single-name, event-driven move no basket of diagnostics peers broke out alongside it, so treat the strength as company-specific rather than sector rotation. That absence of cluster confirmation is why chasing the high-of-year bar carries no momentum-crowd cushion.